Isomorphic Labs announced on November 17, 2026, that it had raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital. The company also said it was scaling its proprietary drug-design engine, IsoDDE, and its pipeline of AI-designed therapeutic candidates, according to its announcement.
The completed round is a later development in the fundraising story covered in NeoTeo’s earlier report.
Who participated in the Series C?
Isomorphic Labs named Andreessen Horowitz (a16z) and several unnamed new investors as participants. Alphabet continued significant investment, and the company listed its existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund as participants too.
The company’s stated scale-up focus is specific: IsoDDE and its pipeline of AI-designed therapeutic candidates.
What Isomorphic Labs says it is scaling
IsoDDE is Isomorphic Labs’ proprietary engine for drug design. Alongside it, the company said it was scaling a pipeline of AI-designed therapeutic candidates—potential medicines under development.
How pharmaceutical partnerships fit into the work
In an interview published November 3, before the financing announcement, Isomorphic Labs president Max Jaderberg discussed the company’s mix of internal drug-discovery programs and pharmaceutical partnerships, including work with Eli Lilly, Novartis and Johnson & Johnson. He also described partnership arrangements involving upfront payments, milestones and downstream royalties, and discussed clinical and regulatory hurdles in developing medicines for patients.